NEW YORK, NY — (Marketwire) — 01/02/12 — Major Pharmaceutical companies are expected to face mounting pressures going forward as major patents for big brand drugs expire and the regulatory landscape in the United States and Europe makes it more challenging for new drugs to enter the market. A report issued by management consulting firm McKinsey in late 2011 went as far as to claim “the good old days of the pharmaceutical industry are gone forever.” The Paragon Report examines the outlook for companies in the Drug Manufacturers – Major Industry and provides equity research on Merck & Co. Inc. (NYSE: MRK) and AstraZeneca Plc (NYSE: AZN) (LSE: AZN). Access to the full company reports can be found at:
According to a recent report from Reuters, several drug makers, “under pressure to streamline operations in the face of rising costs and slowing sales,” are looking to the automotive industry for tips on boosting their profits. GlaxoSmithKline teamed with McLaren in September to get innovation and process know-how from its Formula One engineers. Meanwhile, in 2009, AstraZeneca looked to Jaguar Land Rover, part of India-s Tata Motors, for manufacturing advice.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Drug Manufacturers – Major Industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
In the UK, a multi-million dollar package of measures was outlined by the Prime Minister David Cameron last month to support the UK-s life sciences industry and promote faster access to new medicines for patients. The package included a $281.3 million fund to support the next medical breakthroughs.
According to a report from The Telegraph “the idea is to carve a new research-friendly landscape that will allow the UK to reclaim its position at the top table” in Big Pharma.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at